Q-omics provides the consensus-scored FANCD2OS profile across patient tissues and cancer cell-line models. FANCD2OS expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FANCD2OS is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, FANCD2OS RNA expression shows 16,131 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, BLCA, and GBM as cancer lineages where FANCD2OS shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FANCD2OS — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FANCD2OS survival associations across molecular data types. FANCD2OS RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FANCD2OS RNA expression–survival associations across cancer types. High FANCD2OS expression shows unfavorable associations in KIRC, ACC, LGG and MESO, but favorable associations in SKCM and UVM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FANCD2OS RNA expression.
This table summarizes FANCD2OS tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for FANCD2OS. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FANCD2OS shows higher tumor expression in BLCA, LUAD, COAD, UCEC, LUSC and READ. The BLCA box plot shows higher FANCD2OS RNA expression in tumor versus normal tissue (log2 FC = +0.150, t-test p = .002).
This table shows molecular features associated with FANCD2OS in patient tissues and cancer cell lines. In patient samples, FANCD2OS shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, FANCD2OS RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Lymphoma.
